Progress In Research Of PCSK9 Inhibitors In The Treatment Of Cardiovascular Diseases

Recent studies have shown that proprotein convertase subtilisin/kexin type 9 inhibitor can significantly reduce the low-density lipoprotein cholesterol levels and cardiovascular events.It is safe and tolerant.It can be used in patients with familial hypercholesterolemia and those who are statin-intolerable but need to further lower cholesterol levels.In addition,with the further study of the proprotein convertase subtilisin/kexin type 9,researchers have discovered the proprotein convertase subtilisin/kexin type9 inhibitor may be involved in multiple metabolic pathways,such as anti-inflammatory responses,regulating oxidative stresses,improving the vascular endothelial functions,stabilizing the plaques,inhibiting the formation of thrombosis and so on.It is suggested that proprotein convertase subtilisin/kexin type 9 inhibitor may play an anti-atherosclerotic effect through pathways other than cholesterol metabolism.This finding is expected to increase the clinical value of proprotein convertase subtilisin/kexin type 9 inhibitor in cardiovascular diseases.This article reviews the research progress of proprotein convertase subtilisin/kexin type9 inhibitors.